Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
The REMAP-CAP study is looking at the best ways to treat adults who are very unwell with lung infections such as severe pneumonia, the flu, or COVID-19, and need care in an intensive care unit (ICU). It's a special type of study that allows doctors to test many different treatments at the same time to see which ones are most effective. This flexible design means the study can quickly adapt to new information, helping doctors make better decisions about care. The goal is to improve how patients recover from these serious illnesses. This study can also quickly adapt to new health crises, like a pandemic, to find treatments for new viruses.
במבט חטוף
על מה המחקר הזה?
When someone is very ill with a serious lung infection, like severe pneumonia, the flu, or COVID-19, they often need to be looked after in an intensive care unit (ICU). In the ICU, doctors use many different treatments to help patients get better and fight off the infection. While doctors know many treatments are helpful, it's not always clear which combination works best for different people.
This study, called REMAP-CAP, is designed to help doctors figure out the most effective ways to treat these severe lung infections. It's a clever type of study that can test many different treatments all at once. What's more, it's 'adaptive', meaning it can learn from the patients already in the study. This helps the study identify promising treatments faster and direct new patients towards the treatments that seem to be working best.
The main aim is to improve how patients recover from these serious lung infections. It also acts like a flexible research 'platform' that can quickly start looking for treatments if a new widespread illness, like a pandemic, emerges. This means it can rapidly respond to new health challenges and continue to find the best care for patients.
נקודות עיקריות
- Targets severe lung infections like pneumonia, flu, and COVID-19.
- Aims to find the best combinations of existing treatments.
- Can test many treatments at once and adapt quickly.
- Helps improve care for very unwell patients in intensive care.
- Can rapidly respond to new health crises, like pandemics.
מי עשוי להיות זכאי?
Generally, to join the main REMAP-CAP study, you need to be an adult (18 or over) admitted to an intensive care unit (ICU) because of a severe lung infection, like pneumonia, within two days of getting to the hospital. Your doctors would have seen signs of a lung infection and scans showing changes in your lungs. You would also need support for your organs, such as help with breathing or medication to support your blood pressure.
האם מחקר זה יכול להתאים לך?
ענה על השאלות המהירות הללו כדי לבדוק אם אתה עשוי להיות זכאי. זהו מדריך בלבד — צוות המחקר מקבל את ההחלטה הסופית.
- האם אתה בן 18 או יותר?
- Have you been admitted to intensive care for a severe lung infection?
- Did you come to the ICU within 48 hours of being admitted to the hospital?
- Do you need support for breathing or blood pressure in the ICU?
מה כרוך בהשתתפות?
If you are asked to join this study, it means your doctors believe you could benefit from it. You would continue to receive the best care for your condition, and the study would involve trying different combinations of existing treatments. This includes various medicines for infection, inflammation, or to prevent blood clots. There are no extra hospital visits or special appointments as part of the study; all monitoring would happen as part of your usual intensive care. The study aims to understand the best treatment approaches and would continue for as long as you need intensive care, with doctors monitoring your progress carefully.
סיכונים ותועלות פוטנציאליים
Locations (408)
- University of Floridaמיקוד מאומתג'קסונוויל, ארצות הברית· גיוס
- Augusta Universityמיקוד מאומתאוגוסטה, ארצות הברית· עדיין לא מגייסים
- University of Illinois Healthמיקוד מאומתשיקגו, ארצות הברית· גיוס
- Tulane Medical Centerמיקוד מאומתניו אורלינס, ארצות הברית· עדיין לא מגייסים
- אוניברסיטת מישיגןמיקוד מאומתאן ארבור, ארצות הברית· גיוס
- מרכז הסרטן ממוריאל סלואן קטרינגמיקוד מאומתניו יורק, ארצות הברית· גיוס
- Wake Forest Baptist Healthמיקוד מאומתוינסטון-סאלם, ארצות הברית· עדיין לא מגייסים
- The Ohio State University Wexner Medical Centerמיקוד מאומתקולומבוס, ארצות הברית· גיוס
- Oregon Health and Science Universityמיקוד מאומתפורטלנד, ארצות הברית· גיוס
- University of Pittsburgh Medical Centreמיקוד מאומתפיטסבורג, ארצות הברית· גיוס
- Brown University - Rhode Island Hospitalמיקוד מאומתProvidence, United States· עדיין לא מגייסים
- Canberra Hospitalמיקוד מאומתCanberra, Australia· גיוס
שאלות נפוצות
What kind of infections does this study look at?
It looks at serious lung infections like pneumonia, the flu, and severe COVID-19 that require intensive care.
Why is this study different from others?
It can test many treatments at once and adapt quickly, learning from patients already in the study to find better treatments faster.
Will I get special treatment if I join?
You will receive the best possible care, and the study helps doctors choose the most effective combination of existing treatments for you.
האם אצטרך לשלם על משהו?
No, all care and treatments related to the study are part of your hospital care and involve no extra cost to you.
האם אני יכול לעזוב את המחקר אם אשנה את דעתי?
Yes, you or your family can decide to withdraw from the study at any time. Your medical care will not be affected.
כיצד לגלות עוד
Cameron Green, MSc
תמיד התייעץ עם רופא המשפחה או המומחה שלך לפני שתחליט להשתתף במחקר.
מעוניינים להשתתף?
דיון
דיון קהילתי
מופעל על ידי הפורום שלנו ב community.patient.info. אנא היו מכבדים — זה אינו ייעוץ רפואי.